You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 1
  • LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study

Citation Tools

Article menu

Download PDFPDF

Short Oral Presentation
Short oral presentation session 3: SLE biomarkers 1
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Michelle Kahlenberg J, Sanz I, Wu C, et al
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
Lupus Science & Medicine 2023;10:doi: 10.1136/lupus-2023-KCR.56